Detalhe da pesquisa
1.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol
; 80(3): 419-430, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984709
2.
Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
Liver Int
; 44(1): 39-51, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37698034
3.
Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.
J Gastroenterol Hepatol
; 39(3): 568-575, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114452
4.
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™.
J Viral Hepat
; 30(4): 335-344, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601668
5.
Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
Hepatology
; 76(6): 1576-1586, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567545
6.
Improved survival of cirrhotic patients with infections in Australian and New Zealand ICUs between 2005 and 2017.
Liver Int
; 43(1): 49-59, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35532544
7.
Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle.
J Gastroenterol Hepatol
; 38(10): 1823-1831, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37571988
8.
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
Dig Dis Sci
; 68(1): 291-303, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552941
9.
Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study.
Intern Med J
; 53(11): 2065-2072, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880362
10.
A Mediterranean and low-fat dietary intervention in non-alcoholic fatty liver disease patients: Exploring participant experience and perceptions about dietary change.
J Hum Nutr Diet
; 36(3): 592-602, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962482
11.
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Clin Gastroenterol Hepatol
; 20(10): 2296-2306.e6, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34768009
12.
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
Hepatology
; 74(4): 1737-1749, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704806
13.
A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
Liver Int
; 42(3): 522-531, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34821021
14.
Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial.
Liver Int
; 42(6): 1308-1322, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357066
15.
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up.
BMC Gastroenterol
; 22(1): 339, 2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820850
16.
Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
J Gastroenterol Hepatol
; 37(2): 395-403, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34693553
17.
Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis.
Dig Dis Sci
; 67(7): 3356-3365, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34231100
18.
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Clin Infect Dis
; 73(9): e3288-e3295, 2021 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887983
19.
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
J Hepatol
; 75(3): 524-535, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33887358
20.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309